Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley(Liver Institute Northwest), Michael Fried(University of North Carolina at Chapel Hill), Phillip S. Pang(Gilead Sciences (United States)), K. Rajender Reddy(Hospital of the University of Pennsylvania), David Pound(Orthopaedic Research Foundation), Eugene R. Schiff(University of Miami), Stuart C. Gordon(United States Department of Veterans Affairs), William T. Symonds(Gilead Sciences (United States)), Mario Chojkier(San Francisco VA Medical Center), Paul J. Pockros(Scripps Clinic), Di An(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Michael J. Ryan(Digestive & Liver Disease Specialists), Vinod K. Rustgi, Eric Lawitz(The University of Texas at San Antonio Health Science Center), Lorenzo Rossaro(University of California Davis Medical Center), Reem Ghalib(Clinical Research Institute), G. Mani Subramanian(Pacific Biosciences (United States)), David Bernstein, Evguenia S. Svarovskaia(University of Miami), Robert Herring(Quality Research), Robert H. Hyland(Gilead Sciences (United States)), Mitchell L. Shiffman(Bon Secours Health System), Andrew J. Muir(Duke Medical Center), Adrian M. Di Bisceglie(Saint Louis University)
Cited by 1,125
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k